Vera Therapeutics Announces Positive Week 36 Safety and Efficacy Results in Phase 2b Clinical Trial of Atacicept in IgA Nephropathy

Vera Therapeutics
Vera Therapeutics (VERA) announced that Phase 2b ORIGIN clinical trial of atacicept for IgA nephropathy  met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR through week 36. The week 36 results of ORIGIN trial were presented at the 60th European Renal Association (ERA

This content is for paid subscribers.
Please click here to subscribe or here to log in.